The Oral Microbiome in OSCC
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04925700 |
Recruitment Status :
Completed
First Posted : June 14, 2021
Last Update Posted : November 18, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Oral Cancer | Dietary Supplement: ProDentis Lozenge Other: Placebo Lozenge | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 20 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | The Oral Microbiome in Oral Squamous Cell Carcinoma |
Actual Study Start Date : | April 20, 2022 |
Actual Primary Completion Date : | October 10, 2023 |
Actual Study Completion Date : | October 10, 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: Probiotic Lozenge |
Dietary Supplement: ProDentis Lozenge
1-2 ProDentis Lozenges per day |
Placebo Comparator: Placebo Lozenge |
Other: Placebo Lozenge
1-2 Placebo Lozenges per day |
- Assessment of changes in the oral microbiome composition over time [ Time Frame: Up to 3 months ]16S Genomic Profiling will be done in all recruited subjects via oral swab of pre-cancerous or cancerous oral lesion
- Determine the Effect of ProDentis on the Oral Microbiome [ Time Frame: Up to 3 months ]Pre-Cancerous lesion is treatment planned as "watch-and-wait" or oral lesion is not present, recruited subjects will be randomly assigned to either the probiotic lozenge or placebo lozenge group.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years to 89 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Adults (21-70 years old) who have been diagnosed with oral dysplasia or that have been treatment-planned as wait and watch or
- Adults (21-70 years old) or who have been diagnosed with oral squamous cell carcinoma, or matched healthy controls free of any oral lesions
Exclusion Criteria:
- Adults who have had a course of antibiotics that was completed less than 3 months prior to the study;
- Adults with any immunosuppressive condition or medication that would put the subject at risk of consuming daily probiotics;
- Adults who regularly use probiotic dietary supplements
- Adults that have alcohol/tobacco use history that does not match study population - this if for the healthy controls arm only.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04925700
United States, Iowa | |
University of Iowa College of Dentistry and Dental Clinics | |
Iowa City, Iowa, United States, 52242 |
Principal Investigator: | David Drake, MS, PhD | University of Iowa College of Dentistry |
Responsible Party: | David R. Drake, Professor, University of Iowa |
ClinicalTrials.gov Identifier: | NCT04925700 |
Other Study ID Numbers: |
202012278 |
First Posted: | June 14, 2021 Key Record Dates |
Last Update Posted: | November 18, 2023 |
Last Verified: | November 2023 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Mouth Neoplasms Head and Neck Neoplasms Neoplasms by Site |
Neoplasms Mouth Diseases Stomatognathic Diseases |